drugset / Trial / NCT02122471

12-Week Study of Plecanatide for CIC (The National CIC3 Study)

NCT02122471

Phase 3 Completed 1410 enrolled Bausch Health Americas, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to confirm that the investigational medication, plecanatide, is safe and effective in treating chronic idiopathic constipation.

Timeline

Start
2014-04
Primary completion
2015-05
Completion
2015-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Plecanatide Peptide 3 mg
Subject Plecanatide Peptide 6 mg

Indications